Brought to you by 
Gilead jumps further into cancer with $375mm Calistoga purchase
25 Feb 2021
Executive Summary
Gilead Sciences Inc. will pay $375mm cash to acquire privately held Calistoga Pharmaceuticals Inc. (cancer and inflammation therapies). Gilead has also agreed to pay up to an additional $225mm in earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead jumps further into cancer with $375mm Calistoga purchase
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice